正电子发射断层扫描（PET）引导下的霍奇金淋巴瘤和侵袭性非霍奇金淋巴瘤的个体化治疗。
PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
机构信息
Division of Cancer Sciences, University of Manchester, Manchester, UK.
Department of Medical Oncology, The Christie Hospital NHS Foundation Trust, Manchester, UK.
出版信息
Br J Radiol. 2021 Nov 1;94(1127):20210576. doi: 10.1259/bjr.20210576. Epub 2021 Sep 14.
Abstract
FDG-PET scanning has a central role in lymphoma staging and response assessment. There is a growing body of evidence that PET response assessment during and after initial systemic therapy can provide useful prognostic information, and PET response has an evolving role in guiding patient care. This review provides a perspective on the role of PET response assessment for individualised management of patients with the most common aggressive lymphomas, Hodgkin lymphoma and diffuse large B-cell lymphoma.
摘要
FDG-PET 扫描在淋巴瘤分期和反应评估中具有核心作用。越来越多的证据表明，在初始全身治疗期间和之后进行 PET 反应评估可以提供有用的预后信息，并且 PET 反应在指导患者治疗方面发挥着不断发展的作用。本文就 PET 反应评估在常见侵袭性淋巴瘤（霍奇金淋巴瘤和弥漫性大 B 细胞淋巴瘤）患者个体化管理中的作用提供了一些观点。
相似文献
1
PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
Br J Radiol. 2021 Nov 1;94(1127):20210576. doi: 10.1259/bjr.20210576. Epub 2021 Sep 14.
2
F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?
J Nucl Med. 2017 Oct;58(10):1539-1544. doi: 10.2967/jnumed.116.181347. Epub 2017 Aug 10.
3
FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):97-110. doi: 10.1007/s00259-017-3690-8. Epub 2017 Apr 14.
4
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.
5
Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
Pediatr Radiol. 2019 Oct;49(11):1545-1564. doi: 10.1007/s00247-019-04529-8. Epub 2019 Oct 16.
6
The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
Eur J Pediatr. 2013 Jun;172(6):733-8. doi: 10.1007/s00431-013-1993-8. Epub 2013 Apr 5.
7
New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
Radiol Clin North Am. 2008 Mar;46(2):213-23, vii. doi: 10.1016/j.rcl.2008.03.003.
8
The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
Future Oncol. 2013 Jun;9(6):807-15. doi: 10.2217/fon.13.55.
9
18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
J Nucl Med. 2008 Jan;49(1):9-12. doi: 10.2967/jnumed.107.046292. Epub 2007 Dec 12.
10
2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Semin Radiat Oncol. 2007 Jul;17(3):190-7. doi: 10.1016/j.semradonc.2007.02.005.
引用本文的文献
1
Impact of Modern Low Dose Involved Site Radiation Therapy on Normal Tissue Toxicity in Cervicothoracic Non-Hodgkin Lymphomas: A Biophysical Study.
Cancers (Basel). 2023 Dec 5;15(24):5712. doi: 10.3390/cancers15245712.
2
Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT.
Blood Res. 2022 Apr 30;57(S1):75-78. doi: 10.5045/br.2022.2022055.
3
Lymphoma: New Diagnosis and Current Treatment Strategies.
J Clin Med. 2022 Mar 19;11(6):1701. doi: 10.3390/jcm11061701.
4
Metabolic response to radiation therapy in cancer.
Mol Carcinog. 2022 Feb;61(2):200-224. doi: 10.1002/mc.23379. Epub 2021 Dec 27.
5
Lymphoma: advances in imaging and radiotherapy - introductory editorial.
Br J Radiol. 2021 Nov 1;94(1127):20219005. doi: 10.1259/bjr.20219005.
本文引用的文献
1
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.
Blood Adv. 2021 May 11;5(9):2375-2384. doi: 10.1182/bloodadvances.2021004467.
2
Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2021 Mar 4;384(9):842-858. doi: 10.1056/NEJMra2027612.
3
PET response-guided radiotherapy for advanced DLBCL?
Blood. 2021 Feb 18;137(7):866-867. doi: 10.1182/blood.2020008740.
4
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X.
5
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Blood. 2021 Apr 29;137(17):2307-2320. doi: 10.1182/blood.2020008750.
6
Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP.
Blood. 2021 Feb 18;137(7):929-938. doi: 10.1182/blood.2020005846.
7
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
Blood. 2021 Jan 7;137(1):39-48. doi: 10.1182/blood.2020005112.
8
Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
Cancer Med. 2020 Sep;9(18):6565-6575. doi: 10.1002/cam4.3298. Epub 2020 Jul 25.
9
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
J Clin Oncol. 2020 Sep 10;38(26):3003-3011. doi: 10.1200/JCO.20.00999. Epub 2020 Jul 13.
10
Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach.
Blood. 2020 Dec 10;136(24):2803-2811. doi: 10.1182/blood.2019004296.
Zotero 插件